Start here if you're new
what it is
Cumberland sells niche hospital and GI drugs, while trying to turn a phase II pipeline into something bigger.
how it gets paid
Last year Cumberland Pharma made $45M in revenue.
why it's growing
Revenue grew 225.5% last year. The latest quarter showed real top-line improvement, with revenue up 31% vs. prior year.
what just happened
Quarterly revenue reached $14M, up 31% vs. prior year, but Cumberland still lost $0.09 a share.
At a glance
C++ balance sheet — some cracks in the foundation
40/100 earnings predictability — expect surprises
-$0.46 fy2024 eps est
$38M fy2024 rev est
6.3% operating margin
xvary composite: 32/100 — weak
What they do
Cumberland sells niche hospital and GI drugs, while trying to turn a phase II pipeline into something bigger.
Cumberland's edge is not size. It is access. You are looking at a company with 7 FDA-approved brands and just 91 employees, selling into hospital acute care and gastro markets where small products can still matter. That setup keeps overhead leaner than big pharma, so a few million dollars of extra sales can move a $45M company fast.
How they make money
$45M
annual revenue · their business grew +225.5% last year
total revenue
$45M
+225.5%
The products that matter
H. pylori infection treatment
Talicia
core promoted brand
Talicia matters because the entire company produced $45M in revenue last year. In a business that size, one promoted drug can move the whole income statement.
portfolio anchor
acid reducer commercialization
Omeprazole
partnered commercialization
This partnership matters because analysts only expect $38M in FY2024 revenue. You do not need a blockbuster to matter here. You need fewer misses.
execution dependent
branded hospital and GI portfolio
Acute care and gastroenterology drugs
the full commercial base
The whole portfolio produced $45M last year, but the next full-year estimate sits at $38M. That is the commercial problem in one line.
small base, big swings
Key numbers
-$0.46
fy2024 eps est
$38M
fy2024 rev est
n/a
trailing p/e
n/a
dividend yield
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $10M (18% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for CPIX right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Quarterly revenue reached $14M, up 31% vs. prior year, but Cumberland still lost $0.09 a share.
The latest quarter showed real top-line improvement, with revenue up 31% vs. prior year. The problem is simple: better sales still did not turn into profit, and 2024 stayed negative quarter after quarter.
$14M
revenue
-$0.09
eps
31%
revenue growth
the number that mattered
$14M matters because this company needs every extra sales dollar it can get while operating margin is still -6.3%.
source: EDGAR filing, latest quarter
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is Talicia-led sales weakness inside a $45M revenue base.
med
sales contraction
Q4 2025 revenue fell 31% from a year ago. For a company this size, that is not a soft patch. It is a direct threat to the whole turnaround case.
If full-year revenue lands near the $38M estimate instead of last year's $45M, you are looking at a smaller business with the same overhead problem.
med
product concentration
There is no diversified giant portfolio here. Talicia and a small set of promoted brands carry unusual weight inside a $45M revenue company.
One product miss can ripple across the entire P&L because there is no larger segment mix to hide it.
med
limited financial flexibility
The balance sheet is graded C++ and long-term debt stands at $10M, or 18% of capital. That is manageable until operating results keep slipping.
Losses matter more when your financial cushion is already below average.
med
thin sponsorship and volatility
Institutional ownership data is limited and price stability scores just 5 out of 100. Micro-caps without deep sponsorship rarely get the benefit of the doubt.
That can turn operational disappointment into outsized stock moves very quickly.
A $45M company with a C++ balance sheet and a $38M revenue estimate does not need a disaster to disappoint you. It just needs the slide to continue.
source: institutional data · regulatory filings · risk analysis
Pay attention to
trend
next revenue print
The whole page turns on this. After a 31% drop in Q4, you need to see whether sales stabilize or keep stepping down.
metric
FY2024 revenue vs. $38M estimate
That estimate is your current anchor. Beat it and the story gets breathing room. Miss it and the market will keep treating this as a shrinking asset.
calendar
Q1 2026 earnings report
Due in May 2026. You are looking for evidence that the last quarter was an outlier, not the new baseline.
risk
losses holding near -$0.46 EPS territory
This stock does not have positive earnings to absorb setbacks. If losses fail to improve, valuation stays narrative-driven and fragile.
Analyst rankings
earnings predictability
40 / 100
In human-speak, analysts do not trust the quarterly cadence here. Expect surprises.
beta
0.8
Beta measures market sensitivity. A 0.8 beta means it has moved less than the market historically, but company-specific risk still dominates this name.
risk rank
5
A risk rank of 5 means safer than only 5% of stocks. That is the market's polite way of saying this is a high-risk micro-cap.
source: institutional data
Institutional activity
institutional ownership data for CPIX is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$3
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive